Mustang Bio Inc
MBIO0.787USD
+0.075+10.53%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
5.75MMarket Cap
LossP/E TTM
More Details of Mustang Bio Inc Company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Mustang Bio Inc Info
Ticker SymbolMBIO
Company nameMustang Bio Inc
IPO dateAug 22, 2017
CEOLitchman (Manuel)
Number of employees6
Security typeOrdinary Share
Fiscal year-endAug 22
Address95 Sawyer Rd
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone17816524500
Websitehttps://www.mustangbio.com/
Ticker SymbolMBIO
IPO dateAug 22, 2017
CEOLitchman (Manuel)
Company Executives of Mustang Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.56K
+66.00%
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
375.00
-4.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Mr. David Jin
Mr. David Jin
Director
Director
286.00
+247.00%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
145.00
-247.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.56K
+66.00%
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
375.00
-4.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Mr. David Jin
Mr. David Jin
Director
Director
286.00
+247.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 15 hours ago
Updated: 15 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
4.43%
BlackRock Institutional Trust Company, N.A.
1.31%
Kestra Advisory Services, LLC
1.02%
The Vanguard Group, Inc.
0.90%
Geode Capital Management, L.L.C.
0.41%
Other
91.93%
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
4.43%
BlackRock Institutional Trust Company, N.A.
1.31%
Kestra Advisory Services, LLC
1.02%
The Vanguard Group, Inc.
0.90%
Geode Capital Management, L.L.C.
0.41%
Other
91.93%
Shareholder Types
Shareholders
Proportion
Corporation
4.43%
Investment Advisor
3.44%
Investment Advisor/Hedge Fund
0.41%
Hedge Fund
0.40%
Venture Capital
0.29%
Individual Investor
0.05%
Research Firm
0.04%
Other
90.93%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
67
280.77K
4.35%
+37.29K
2025Q3
66
133.63K
2.09%
-69.17K
2025Q2
79
500.57K
14.17%
+141.50K
2025Q1
99
1.35M
61.40%
+978.22K
2024Q4
107
246.39K
20.57%
+127.81K
2024Q3
122
111.37K
16.10%
+44.38K
2024Q2
137
71.29K
10.74%
+5.47K
2024Q1
164
58.94K
30.95%
-18.94K
2023Q4
172
59.40K
38.79%
+2.99K
2023Q3
181
115.34K
86.47%
+11.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fortress Biotech Inc
257.53K
3.99%
-666.00
-0.26%
Nov 18, 2025
BlackRock Institutional Trust Company, N.A.
84.73K
1.31%
+83.08K
+5026.01%
Sep 30, 2025
Kestra Advisory Services, LLC
66.11K
1.02%
+66.11K
--
Sep 30, 2025
The Vanguard Group, Inc.
57.86K
0.9%
+57.86K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
26.42K
0.41%
+10.34K
+64.27%
Sep 30, 2025
XTX Markets LLC
18.77K
0.29%
+18.77K
--
Sep 30, 2025
CFO4Life
10.46K
0.16%
+10.46K
--
Sep 30, 2025
Renaissance Technologies LLC
11.80K
0.18%
+11.80K
--
Sep 30, 2025
SBI Securities Co., Ltd.
2.01K
0.03%
+1.50K
+299.80%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Jan 14, 2025
Merger
50→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
Apr 03, 2023
Merger
15→1
